Mandate

Vinge advises Thermo Fisher in connection with the acquisition of Olink

Vinge has advised Thermo Fisher Scientific Inc., (”Thermo Fisher”), the world leader in serving science, with annual revenue over $40 billion, in connection with its acquisition of Olink Holding AB (publ) (“Olink”).

Thermo Fisher will commence a tender offer to acquire all of the outstanding Olink common shares and all American Depositary Shares for $26.00 per common share in cash, representing $26.00 per American Depositary Share. The transaction values Olink at approximately $3.1 billion which includes net cash of approximately $143 million.

Olink is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala and the company’s shares are since 2021 traded on Nasdaq Global Market.

Vinge’s team mainly consisted of Jonas Bergström, Erik Sjöman, Samra Tesser, Linnéa Sellström and Anna Svensson (M&A and capital markets), Cecilia Möller Norstedt (litigation), Mattias Schömer and Emelie Svanberg (tax), Sam Seddigh, (employment), Daniel Wendelsson, Victoria Fredén and Hampus Peterson (FDI) and Malin Malm Waerme (IP).

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025